• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Study shows combination stroke therapy safe and effective
The combination of the clot-busting drug tPA with an infusion of the antiplatelet drug eptifibatide dissolves blood clots safely and more quickly than tPA alone, a study led by University of Cincinnati (UC) researchers has found. Results from the study, known as the CLEAR-ER Stroke Trial, are published online in the journal Stroke: Journal of the American Heart Association. UC was the coordinating center for the trial, which included nine medical centers comprising 21 hospitals...
Source: Health News from Medical News Today - August 1, 2013 Category: Consumer Health News Tags: Stroke Source Type: news

Treatment of progressive ischemic stroke with low ‑dose eptifibatide: A retrospective case‑control study
Exp Ther Med. 2022 Nov 22;25(1):22. doi: 10.3892/etm.2022.11721. eCollection 2023 Jan.ABSTRACTProgressive ischemic stroke (PIS) is a therapeutic challenge in clinical practice. The present retrospective study aimed to investigate the safety and effectiveness of eptifibatide in the treatment of PIS. The present study enrolled patients with PIS admitted to Xiangtan Central Hospital (Xiangtan, China) between March 2020 and March 2021 with National Institutes of Health Stroke Scale (NIHSS) progression scores of ≥2 points during the initial 72 h. Patients were then divided into two groups according to their different anti-pla...
Source: Experimental and Therapeutic Medicine - December 23, 2022 Category: General Medicine Authors: Long Luo Jinsheng Lin Ye Deng Zhigang Li Ying Yuan Wen Zhang Source Type: research

UC lands largest grant ever for emergency medicine
The University of Cincinnati has been awarded a $29 million grant to study a clot-busting drug used to treat acute ischemic stroke, the largest amount ever awarded to the College of Medicine ’s Department of Emergency Medicine. The grant by the National Institutes of Health will fund research on the effectiveness of combining a drug known as tissue plasminogen activator, or tPA, with the blood thinners argatroban or eptifibatide. Plans call for 110 hospitals to take part in the stud y run through…
Source: bizjournals.com Health Care:Biotechnology headlines - June 1, 2018 Category: Biotechnology Authors: Barrett J. Brunsman Source Type: news